Abstract:INTRODUCTION AND OBJECTIVES: According to data from SEER (http://seer.cancer.gov/) in the United States, bladder cancer (BC) has improved 5-year survival rate by only 3% in the last two decades.D-3-phosphoglycerate dehydrogenase (PHGDH) is an enzyme that converts 3-phosphoglycerate on glycolysis system and induces metabolism to serine synthesis.Cancers require serine to maintain rapid, sustained and uncontrollable proliferation.Recently it has been reported that PHGDH can be a therapeutic target in breast cancer and melanoma, on the other hand there has been no report on BC.The aim of this study is to evaluate therapeutic possibility regarding PHGDH in BC.METHODS: Clinical significance of PHGDH in BC was analyzed using The Cancer Genome Atlas (TCGA) which is a public database.In addition, the effect of PHGDH inhibitor (NCT-503) and si-RNA against PHGDH was evaluated by cell proliferation and apoptosis assay in BC cell lines (T24, BOY, KK47, UMUC-3, J82).In xenograft assay, PHGDH knockdown efficiency was investigated using sh-RNA against PHGDH.Furthermore, additive effect of the PHGDH inhibitor under Gemcitabine and Cisplatin (GC) administration was examined.RESULTS: In the PHGDH high expression group (n [ 157), the prognosis was poor (P [ 0.0032) compared with the low expression group (n [ 247), and PHGDH was found to be an independent poor prognostic factor (P [ 0.001) in multivariate analysis.The PHGDH inhibitor and PHGDH si-RNAs significantly inhibited proliferative ability through induction of apoptosis (P < 0.05) in BC cell lines.Western blot analyses showed that Ki-67 expression was markedly repressed and cleaved caspase-3 expression was increased in PHGDH knockdown BC cells compared with those in control BC cells.Additionally, cells with PHGDH overexpression promoted tumor cell viability in comparison to control cells.In xenograft assay, PHGDH knockdown by sh-RNA significantly inhibited tumor progression compared to the vehicle group (P < 0.05).Furthermore, the combination treatment between PHGDH inhibitor and GC showed synergistic tumor suppressive effect compared to each single agent group (P < 0.05) in proliferation assay.CONCLUSIONS: Our study revealed that PHGDH inhibition showed tumor suppressive effects in BC.Furthermore, the combination therapy between PHGDH inhibitor and GC showed synergistic effect in proliferation assay.Novel therapeutic implications through functional analysis of PHGDH in BC were suggested.

MTX-211 Inhibits GSH Synthesis Through Keap1/NRF2/GCLM Axis and Exerts Antitumor Effects in Bladder Cancer.

MLN2238 exerts its anti-tumor effects <i>via</i> regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma

Optimization of BCG Therapy Targeting Neutrophil Extracellular Traps, Autophagy, and Mirnas in Bladder Cancer: Implications for Personalized Medicine

Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells.

Glaucocalyxin A Induces G2/M Cell Cycle Arrest and Apoptosis Through the PI3K/Akt Pathway in Human Bladder Cancer Cells.

Anlotinib Enhances the Therapeutic Effect of Bladder Cancer with GSDMB Expression: Analyzed from TCGA Bladder Cancer Database & Mouse Bladder Cancer Cell Line

MP51-06 SMYD3 INHIBITION INDUCES PROTECTIVE AUTOPHAGY IN BLADDER CANCER VIA MTOR PATHWAY

Inhibitory Role of Proguanil on the Growth of Bladder Cancer Via Enhancing EGFR Degradation and Inhibiting Its Downstream Signaling Pathway to Induce Autophagy

Therapeutic effects and underlying mechanism of poly (L-glutamic acid)-g-methoxy poly (ethylene glycol)/combretastatin A4/BLZ945 nanoparticles on Renca renal carcinoma

NXPH4 Promotes Gemcitabine Resistance in Bladder Cancer by Enhancing Reactive Oxygen Species and Glycolysis Activation through Modulating NDUFA4L2

Gefitinib Reverses PD-L1-Mediated Immunosuppression Induced by long-term Glutamine blockade in Bladder Cancer

Inhibition of MELK Produces Potential Anti‐tumour Effects in Bladder Cancer by Inducing G1/S Cell Cycle Arrest Via the ATM/CHK2/p53 Pathway

Inhibition of PP2A by LB100 sensitizes bladder cancer cells to chemotherapy by inducing p21 degradation

SLC25A21 Suppresses Cell Growth in Bladder Cancer Via The Reactive Oxygen Species-Mediated Mitochondrion-Dependent Apoptosis Pathway

Inhibition of KDM4A restricts SQLE transcription and induces oxidative stress imbalance to suppress bladder cancer

Discovery of a potential bladder cancer inhibitor CHNQD-01281 by regulating EGFR and promoting infiltration of cytotoxic T cells

Anti-tumor Effects and Cell Motility Inhibition of the DN604-gemcitabine Combined Treatment in Human Bladder Cancer Models.

Ginkgolide B Inhibits Human Bladder Cancer Cell Migration and Invasion Through MicroRNA-223-3p.

G3BP1 and SLU7 Jointly Promote Immune Evasion by Downregulating MHC‐I Via PI3K/Akt Activation in Bladder Cancer

FL118: A potential bladder cancer therapeutic compound targeting H2A.X identified through library screening

Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer